Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;97(8):2133-2142.
doi: 10.1007/s00204-023-03524-1. Epub 2023 May 20.

Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism

Ya-Nan Liu #  1 , Jie Chen #  1 , Jing Wang  1 , Qingqing Li  1 , Guo-Xin Hu  2 , Jian-Ping Cai  3 , Guanyang Lin  4 , Ren-Ai Xu  5
Affiliations

Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism

Ya-Nan Liu et al. Arch Toxicol. 2023 Aug.

Abstract

In this study, the effects of 17 CYP3A4 variants and drug-drug interactions (DDI) with its mechanism on alectinib metabolism were investigated. In vitro incubation systems of rat liver microsomes (RLM), human liver microsomes (HLM) and recombinant human CYP3A4 variants were established. The formers were used to screen potential drugs that inhibited alectinib metabolism and study the underlying mechanism, and the latter was used to determine the dynamic characteristics of CYP3A4 variants. Alectinib and its main metabolite M4 were quantitatively determined by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). The results showed that compared with CYP3A4.1, only CYP3A4.29 showed higher catalytic activity, while the catalytic activity of CYP3A4.4, .7, .8, .12, .14, .16, .17, .18, .19, .20, .23, and .24 decreased significantly. Among them, the catalytic activity of CYP3A4.20 is the lowest, only 2.63% of that of CYP3A4.1. Based on the RLM incubation system in vitro, 81 drugs that may be combined with alectinib were screened, among which 18 drugs had an inhibition rate higher than 80%. In addition, nicardipine had an inhibition rate of 95.09% with a half-maximum inhibitory concentration (IC50) value of 3.54 ± 0.96 μM in RLM and 1.52 ± 0.038 μM in HLM, respectively. There was a mixture of non-competitive and anti-competitive inhibition of alectinib metabolism in both RLM and HLM. In vivo experiments of Sprague-Dawley (SD) rats, compared with the control group (30 mg/kg alectinib alone), the AUC(0-t), AUC(0-∞), Tmax and Cmax of alectinib administered in combination with 6 mg/kg nicardipine were significantly increased in the experimental group. In conclusion, the metabolism of alectinib was affected by polymorphisms of the CYP3A4 gene and nicardipine. This study provides reference data for clinical individualized administration of alectinib in the future.

Keywords: ALK-TKI; Alectinib; CYP3A4; Incubation system; Nicardipine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Androutsopoulos VP, Ruparelia K, Arroo RR, Tsatsakis AM, Spandidos DA (2009a) CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells. Toxicology 264(3):162–170. https://doi.org/10.1016/j.tox.2009.07.023 - DOI - PubMed
    1. Androutsopoulos VP, Tsatsakis AM, Spandidos DA (2009b) Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer 9:187. https://doi.org/10.1186/1471-2407-9-187 - DOI - PubMed - PMC
    1. Androutsopoulos VP, Papakyriakou A, Vourloumis D, Tsatsakis AM, Spandidos DA (2010) Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol Ther 126(1):9–20. https://doi.org/10.1016/j.pharmthera.2010.01.009 - DOI - PubMed
    1. Calvo E, Lee J-S, Kim S-W et al (2019) Modulation of fexofenadine pharmacokinetics by osimertinib in patients with advanced EGFR-mutated non-small cell lung cancer. J Clin Pharmacol 59(8):1099–1109. https://doi.org/10.1002/jcph.1403 - DOI - PubMed
    1. Cleary Y, Gertz M, Morcos PN et al (2018) Model-based assessments of CYP-mediated drug-drug interaction risk of alectinib: physiologically based pharmacokinetic modeling supported clinical development. Clin Pharmacol Ther 104(3):505–514. https://doi.org/10.1002/cpt.956 - DOI - PubMed

LinkOut - more resources